Amgen Stock Soars Near 52-Week High After Earnings Beat and Guidance Raise
Amgen's stock price is near its 52-week high after the biotechnology company reported better-than-expected earnings and updated full-year guidance.
The company posted non-GAAP earnings per share of $6.29 for its latest quarter, exceeding analysts' consensus estimates by $0.67 and marking a year-over-year increase from $6.02.
Amgen's management also set full-year 2026 EPS guidance in the range of $22.30 to $23.50, which is higher than sell-side forecasts.
An insider sale drew attention to the stock's strong run, but analysts note that a realized sale does not necessarily signal weakening confidence.
The company's revenue growth of 12% is driven by double-digit growth from 16 products, and management has slightly raised its 2025 top-line and bottom-line guidance.